Development of an Advanced Injectable Therapy for Ischemic Vascular Disease
Abstract
Cardiovascular diseases are the most common causes of death for Americans and it is estimated that 20% of the population over 65 years of age have peripheral arterial disease. The clinical standard of care for chronic peripheral ischemia includes physical therapy, pharmacological interventions, endovascular stent placement and surgical bypass of stenosed arteries. While these methods can often restore perfusion to the ischemia limb, these therapies often fail in the long term due to continued microvascular disease. In addition, many patients are not unable to be treated with these therapies due to overall poor health or diffuse vascular disease. A promising approach to this problem is to induce the growth of new vessels using angiogenic therapy with growth factors to restore flow to the ischemic tissues. Unfortunately, many clinical trials using growth factors for treating ischemia have shown little benefit for patients. Our group has recently identified that the long-term disease processes in diabetes and hyperlipidemia reduce the levels of the growth factor co-receptorsyndecan-4 in human patients. Loss of this co-receptor would prevent growth factor therapy from being effective in these patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1050514
Entities
People
- Aaron B Baker
Organizations
- University of Texas at Austin